PerkinElmer, Inc. (NYSE:PKI) insider Frank Anders Wilson sold 37,535 shares of PerkinElmer stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $70.14, for a total value of $2,632,704.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of PerkinElmer, Inc. (NYSE PKI) traded up $0.57 on Friday, reaching $70.11. The company had a trading volume of 693,100 shares, compared to its average volume of 632,765. The stock has a market cap of $7,665.06, a PE ratio of 25.01, a P/E/G ratio of 2.08 and a beta of 0.77. PerkinElmer, Inc. has a 1 year low of $50.59 and a 1 year high of $74.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.59 and a quick ratio of 2.09.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 9th. Investors of record on Friday, January 19th will be paid a $0.07 dividend. The ex-dividend date is Thursday, January 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.40%. PerkinElmer’s dividend payout ratio is currently 7.78%.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in PerkinElmer by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 10,886,642 shares of the medical research company’s stock worth $741,816,000 after acquiring an additional 273,975 shares during the period. Janus Henderson Group PLC acquired a new stake in PerkinElmer during the 2nd quarter worth about $436,483,000. BlackRock Inc. boosted its position in PerkinElmer by 2.4% during the 2nd quarter. BlackRock Inc. now owns 5,929,277 shares of the medical research company’s stock worth $404,022,000 after acquiring an additional 141,650 shares during the period. King Luther Capital Management Corp boosted its position in PerkinElmer by 1.3% during the 3rd quarter. King Luther Capital Management Corp now owns 2,562,833 shares of the medical research company’s stock worth $176,759,000 after acquiring an additional 32,248 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in PerkinElmer by 9.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 955,790 shares of the medical research company’s stock worth $65,923,000 after acquiring an additional 86,395 shares during the period. Hedge funds and other institutional investors own 91.66% of the company’s stock.

A number of research analysts recently issued reports on the company. Citigroup reaffirmed a “buy” rating and set a $80.00 target price (up from $74.00) on shares of PerkinElmer in a report on Tuesday, September 26th. ValuEngine cut PerkinElmer from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen reissued a “hold” rating and issued a $70.00 price target on shares of PerkinElmer in a research note on Friday, September 1st. Robert W. Baird reissued a “buy” rating and issued a $72.00 price target on shares of PerkinElmer in a research note on Friday, October 20th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $77.00 price target (down previously from $79.00) on shares of PerkinElmer in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $68.64.

TRADEMARK VIOLATION NOTICE: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/08/frank-anders-wilson-sells-37535-shares-of-perkinelmer-inc-pki-stock.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.